Eli Lilly and Co. shares were down 2.95% at $1,197.23 on Wednesday after the stock reached an all-time intraday high of $1,292.65 and a record close of $1,280.34 on Aug. 19. The pullback appears to reflect consolidation after a strong rally rather than specific negative news. Separately, a study published in Diabetes, Obesity and Metabolism found that adults over 55 with overweight or obesity who used Zepbound had lower healthcare costs than untreated patients, excluding the drug's direct cost. Depending on the analytical method, monthly costs fell by up to 15%, or $181, after six months and up to 38%, or $607, after 12 months. Patients also recorded fewer hospital admissions and emergency-room visits but more routine office visits. After six months, the savings nearly offset the $195 monthly cost of the Medicare GLP-1 Bridge program, while after one year they exceeded the treatment cost.